PHM321 2025/2026 Exam Questions and
Verified Answers | Already Graded A+
Manufacturer of Bayfortus - 🧠 ANSWER ✔✔AstraZeneca & Sanofi
MOA Beyfortus - 🧠 ANSWER ✔✔binds F protein on RSV - preventing virus
fusion
Indication for Beyfortus - 🧠 ANSWER ✔✔Infants and Neonates in 1st RSV season
Infants with high risk in 2nd RSV season
Is Beyfortus Rare disease? - 🧠 ANSWER ✔✔no its common
Administration of Beyfortus - 🧠 ANSWER ✔✔IM by HCP
Competitors for Beyfortus - 🧠 ANSWER ✔✔Palivizumab
Unmet need for Beyfortus - 🧠 ANSWER ✔✔no current treatment for RSV
Reimbursement for Beyfortus - 🧠 ANSWER ✔✔NOC by HC
CADTH and INESS - under review
1
COPYRIGHT@SARAHROSAPERAL 2025/2026. YEAR PUBLISHED 2025. COMPANY REGISTRATION NUMBER: 619652435. TERMS OF USE.
PRIVACY STATEMENT. ALL RIGHTS RESERVED
, Camzyos Manufacturer - 🧠 ANSWER ✔✔Bristol-myers-squibb
Camzyos MOA - 🧠 ANSWER ✔✔reversible inhibitor of cardiac myosin ATPase
reduces actin-myosin cross- bridges
Camzyos Indication - 🧠 ANSWER ✔✔Symptomatic obstructive hypertrophic
cardiomyopathy
adults with NYHA stage 2 to 3 heart failure
Second line to BB or verapamil/diltiazem
Cambzyos Disease state - 🧠 ANSWER ✔✔Common
Route of administration Camzyos - 🧠 ANSWER ✔✔oral capsules
unmet need for camzyos - 🧠 ANSWER ✔✔first therapy targets underlying
pathophysiology
Competitors of Camzyos - 🧠 ANSWER ✔✔Aficamten
Reimbursement of Camzyos - 🧠 ANSWER ✔✔CADTH and INESS reimburse
with conditions
2
COPYRIGHT@SARAHROSAPERAL 2025/2026. YEAR PUBLISHED 2025. COMPANY REGISTRATION NUMBER: 619652435. TERMS OF USE.
PRIVACY STATEMENT. ALL RIGHTS RESERVED
Verified Answers | Already Graded A+
Manufacturer of Bayfortus - 🧠 ANSWER ✔✔AstraZeneca & Sanofi
MOA Beyfortus - 🧠 ANSWER ✔✔binds F protein on RSV - preventing virus
fusion
Indication for Beyfortus - 🧠 ANSWER ✔✔Infants and Neonates in 1st RSV season
Infants with high risk in 2nd RSV season
Is Beyfortus Rare disease? - 🧠 ANSWER ✔✔no its common
Administration of Beyfortus - 🧠 ANSWER ✔✔IM by HCP
Competitors for Beyfortus - 🧠 ANSWER ✔✔Palivizumab
Unmet need for Beyfortus - 🧠 ANSWER ✔✔no current treatment for RSV
Reimbursement for Beyfortus - 🧠 ANSWER ✔✔NOC by HC
CADTH and INESS - under review
1
COPYRIGHT@SARAHROSAPERAL 2025/2026. YEAR PUBLISHED 2025. COMPANY REGISTRATION NUMBER: 619652435. TERMS OF USE.
PRIVACY STATEMENT. ALL RIGHTS RESERVED
, Camzyos Manufacturer - 🧠 ANSWER ✔✔Bristol-myers-squibb
Camzyos MOA - 🧠 ANSWER ✔✔reversible inhibitor of cardiac myosin ATPase
reduces actin-myosin cross- bridges
Camzyos Indication - 🧠 ANSWER ✔✔Symptomatic obstructive hypertrophic
cardiomyopathy
adults with NYHA stage 2 to 3 heart failure
Second line to BB or verapamil/diltiazem
Cambzyos Disease state - 🧠 ANSWER ✔✔Common
Route of administration Camzyos - 🧠 ANSWER ✔✔oral capsules
unmet need for camzyos - 🧠 ANSWER ✔✔first therapy targets underlying
pathophysiology
Competitors of Camzyos - 🧠 ANSWER ✔✔Aficamten
Reimbursement of Camzyos - 🧠 ANSWER ✔✔CADTH and INESS reimburse
with conditions
2
COPYRIGHT@SARAHROSAPERAL 2025/2026. YEAR PUBLISHED 2025. COMPANY REGISTRATION NUMBER: 619652435. TERMS OF USE.
PRIVACY STATEMENT. ALL RIGHTS RESERVED
